| Title |
Publication Date |
Price |
Relevance |
Women's Health
Worldwide Prescription Drug Markets
|
August 2006 |
£2380 |
100 % |
Women's Health
Worldwide Prescription Drug Markets
|
August 2006 |
£1200 |
100 % |
Women's Health: Diagnostic Testing
|
August 2008 |
£1110 |
97 % |
Women's Health Market Outlook to 2011
|
May 2007 |
£1495 |
96 % |
Women's Health - Infertility Drug Pipeline Report
|
February 2008 |
£995 |
95 % |
Women's Health - Contraception Drug Pipeline Report
|
February 2008 |
£995 |
95 % |
Women's Health - Endometriosis Drug Pipeline Report
|
February 2008 |
£995 |
95 % |
Women's Health - Menopausal Symptoms Drug Pipeline Report
|
February 2008 |
£995 |
94 % |
Women's Health - Vaginal Infections Drug Pipeline Report
|
February 2008 |
£995 |
94 % |
Women's Health - Female Sexual Dysfunction Drug Pipeline Report
|
February 2008 |
£995 |
93 % |
Women's Health: Worldwide Prescription Drug Markets, 4th Edition
|
February 2009 |
£1825 |
93 % |
Medical Problems in Women over 70
When Normative Treatment Plans do not Apply
|
April 2007 |
£55 |
64 % |
Women First Healthcare Inc. -Therapeutic Competitors
|
February 2008 |
£175 |
63 % |
Women First Healthcare Inc. -Deals & Alliances Report
|
February 2008 |
£300 |
62 % |
Women's Reproductive Disorders Therapeutics 2008-2018
|
September 2008 |
£1499 |
62 % |
Women First Healthcare Inc.-Deals & Alliances Report
|
March 2009 |
£316 |
62 % |
Women First Healthcare Inc. -Financial Company Report
|
February 2008 |
£175 |
62 % |
Women First Healthcare Inc. -Detailed Product Pipeline
|
February 2008 |
£375 |
62 % |
U.S. Market for Women's Health Devices 2009
|
January 2009 |
£4575 |
50 % |
U.S. Market for Women's Health Devices 2009
|
January 2009 |
£4575 |
50 % |
New Therapeutics and Diagnostics for Women’s Disorders
|
May 2005 |
£2960 |
37 % |
Nutraceuticals
|
April 2007 |
£899 |
35 % |
Sciele Pharma Inc
Premium Company Profile
|
December 2007 |
£265 |
31 % |
Offices of General and Family Practice Physicians in the US
IBISWorld Industry Report
|
August 2007 |
£395 |
28.5 % |
Medical litigation
Health campaigners talk about medical litigation in the USA and Europe
|
March 2006 |
£400 |
28 % |
Mammography World Markets
|
October 2008 |
£2075 |
27.5 % |
Warner Chilcott Ltd
Premium Company Profile
|
January 2008 |
£265 |
25 % |
Atlas of Endometriosis
5th edition
|
September 2007 |
£75 |
24.5 % |
Mayo Clinic Internal Medicine Concise Textbook
|
September 2007 |
£55 |
24.15 % |
Female Sexual Dysfunction
Prescription Drug Pipeline Overview 2007
|
July 2007 |
£2005 |
23.45 % |
CHRISTUS Health - Strategic Analysis Review
|
June 2009 |
£76 |
22.5 % |
2007 U.S. Drugs and Health and Beauty Aids Product Lines
|
April 2007 |
£120 |
22.4 % |
Hologic Medical Device Company Intelligence Report
|
March 2009 |
£295 |
21.5 % |
Mixed Urinary Incontinence
An Opportunity for Novel Drug Therapies
|
April 2006 |
£6510 |
21.5 % |
Launching Combination Products
Brand Extension and Franchise Development Strategies
|
January 2008 |
£1995 |
21 % |
Stress Urinary Incontinence
Opinion Divided on Drug Therapy
|
April 2006 |
£8690 |
20.5 % |
Ethicon Medical Device Company Intelligence Report
|
December 2007 |
£295 |
20 % |
Patients' rights: the views of health campaigners from Eastern Europe
Eastern European health campaigners' latest views on patients' rights in their countries
|
October 2006 |
£400 |
18.55 % |
PepsiCo: The World's Biggest Functional Food Company
10 Case Studies In Its Strategies In Sports Drinks, Fruit Drink, Snack Innovation And Cereals
|
February 2007 |
£145 |
18.55 % |
American Medical Systems Holdings, Inc. - Healthcare - Medical Equipment - SWOT Report
|
September 2008 |
£76 |
18.55 % |
7-Eleven: Towards Healthy Convenience
|
October 2007 |
£75 |
18.5 % |
Partners HealthCare System, Inc. - Strategic Analysis Review
|
March 2009 |
£76 |
17 % |
Australia Pharmaceuticals & Healthcare
|
February 2009 |
£250 |
17 % |
The Pharmaceutical Market: Pakistan
|
November 2007 |
£595 |
16.8 % |
The Medical Device Market: Pakistan
|
November 2007 |
£595 |
16.8 % |
The Medical Device Market: Serbia
|
March 2008 |
£595 |
16.8 % |
Pharmacological and Psychosocial Treatments in Schizophrenia
|
January 2008 |
£35.95 |
16.45 % |
Follicle Stimulating Hormone (FSH)
Competitor Analysis
|
November 2008 |
£150 |
15.5 % |
Wound Care, 3rd. Edition, Vol. III:
Surgical and Trauma Wounds
|
September 2007 |
£1825 |
15 % |
The Overactive Bladder: Evaluation and Management
|
June 2007 |
£125 |
15 % |
Specialty Pharma Market Outlook, The
Key players, new company growth models and emerging opportunities
|
October 2006 |
£1495 |
14.7 % |
Managing Clinical Investigator Compensation
|
May 2009 |
£4695 |
14.7 % |
Health and Wellness Beverages in Ireland
|
November 2006 |
£650 |
14.7 % |
Wyeth - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
14.5 % |
Barr Pharmaceuticals - SWOT Analysis
|
October 2008 |
£66 |
14 % |
Boston IVF Handbook of Infertility
|
March 2007 |
£45 |
14 % |
Success and Failure in Functional Water
Eleven Case Studies From Europe, The U.S. And Asia
|
November 2006 |
£160 |
14 % |
The Medical Device Market: Croatia
|
December 2006 |
£595 |
14 % |
Intermountain Healthcare, Inc. - Strategic Analysis Review
|
March 2009 |
£76 |
14 % |
Seeking Beauty Through Nutrition
|
August 2006 |
£1475 |
14 % |
The Pharmaceutical Market: Croatia
|
December 2006 |
£595 |
14 % |
Reformulation Strategies
Comparisons of Past and Future Reformulation Strategies
|
September 2006 |
£4000 |
14 % |
Schering-Plough
Pipeline ,Products ,Performance ,Potential
|
August 2008 |
£595 |
13.65 % |
Premium Company Profile Antares Pharma
|
November 2007 |
£265 |
13.5 % |
Health Benefit Platforms & Strategies in Breakfast Cereals
17 Key Case Studies
|
January 2007 |
£145 |
13.3 % |
The Pharmaceutical Market: South Africa
|
October 2007 |
£595 |
13 % |
Martek Biosciences Corp: Premium Company Profile
Premium Company Profile
|
January 2008 |
£265 |
13 % |
Hereditary Breast Cancer
|
September 2007 |
£105 |
12.95 % |
Pharmaceutical Regulatory Industry
|
January 2006 |
£2960 |
12.6 % |
Optiscan Imaging Limited Product Pipeline Analysis
|
August 2008 |
£460 |
12.6 % |
Solvay Prospects to 2010
Pipeline, Products,Performance,Potential
|
December 2008 |
£595 |
12.6 % |
The Premenstrual Disorders: PMS and PMDD
|
October 2007 |
£110 |
12.5 % |
Sciele Pharma, Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
12.5 % |
Columbia Laboratories Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
12.5 % |
Sciele Pharma, Inc. - SWOT Analysis
|
December 2008 |
£66 |
12.5 % |
Clarithromycin
Pipeline Developer
|
Ongoing |
£2875 |
12.5 % |
Treating Depression Effectively: Applying Clinical Guidelines
2nd edition
|
August 2007 |
£35 |
12.25 % |
Chinese Markets for Cancer Treatment Drugs
|
September 2005 |
£2440 |
12.25 % |
Pharma R&D Fact Book, The
2006
|
November 2007 |
£495 |
12.25 % |
Ibandronic Acid: Extended Country Coverage
Pipeline Selector
|
Ongoing |
£600 |
12 % |
Ibandronic Acid: Core Country Coverage
Pipeline Selector
|
Ongoing |
£255 |
12 % |
Stakeholder Insight: Osteoporosis
Generic alendronate further establishes oral bisphosphonates as gold standard
|
October 2008 |
£8000 |
11.55 % |
Drospirenone: Core Country Coverage
Pipeline Selector
|
Ongoing |
£255 |
11.5 % |
Capecitabine
Pipeline Developer
|
Ongoing |
£2875 |
11.5 % |
The World Market for Gynaecology
2007-2017
|
September 2007 |
£3200 |
11.5 % |
Drospirenone: Extended Country Coverage
Pipeline Selector
|
Ongoing |
£600 |
11.5 % |
Stakeholder Opinions: Female Sexual Dysfunction
Results from Datamonitor's 2005 physician survey
|
June 2007 |
£2005 |
11.2 % |
UCB Schwarz: PharmaVitae Profile
|
February 2007 |
£3010 |
11.2 % |
Bionovo, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
11.2 % |
Health and Wellness Healthcare Products in India
|
November 2006 |
£650 |
10.85 % |
Major World Markets for Stents and The Economics of Drug-Eluting Technology
|
May 2008 |
£1710 |
10.5 % |
Key Opinion Leaders:
Relationship Management and Segmentation Data
|
February 2009 |
£4695 |
10.5 % |
Health and Wellness Healthcare Products in Ireland
|
December 2006 |
£650 |
10.5 % |
Shire: Pipeline • Products • Performance • Potential
|
December 2008 |
£595 |
10.5 % |
Eye Care in Thailand
|
July 2008 |
£450 |
10.5 % |
Analgesics in Thailand
|
July 2008 |
£450 |
10.5 % |
Digestive Remedies in Thailand
|
July 2008 |
£450 |
10.5 % |
Global Market for Hormonal Contraceptives and Infertility Drugs, 2005-2012; The
|
January 2006 |
£1900 |
10.5 % |
Commercial and Pipeline Insight: HRT for Menopausal Symptoms
A new class restores an old market
|
April 2008 |
£8000 |
10.15 % |
NRT Smoking Cessation Aids in Thailand
|
July 2008 |
£450 |
10.15 % |
Innovations in Cancer
Novel Therapeutics, New Diagnostics and Future R&D Strategies
|
February 2007 |
£1495 |
10 % |
Breast Cancer - Therapeutic And Competitive Insights
|
February 2007 |
£1340 |
10 % |
Maximizing Your Brand Value
|
August 2007 |
£4270 |
9.8 % |
Health and Wellness Healthcare Products in Russia
|
December 2006 |
£650 |
9.8 % |
Medicated Skin Care in Thailand
|
July 2008 |
£450 |
9.8 % |
Vitamins and Dietary Supplements in Thailand
|
July 2008 |
£450 |
9.8 % |
Innovation in Drug Delivery
The future of nanotechnology and non-invasive protein delivery
|
November 2006 |
£1495 |
9.5 % |
Computed Tomography (CT) Systems Market Worldwide 2009
|
April 2009 |
£1520 |
9.5 % |
Next-Generation Nutraceuticals
Food and pharma convergence in disease prevention and personalized nutrition
|
December 2006 |
£1495 |
9.45 % |
Health and Wellness Healthcare Products in Mexico
|
January 2007 |
£650 |
9.45 % |
Pierre Fabre: PharmaVitae Profile
|
November 2006 |
£3000 |
9.1 % |
Urogenital Pain in Clinical Practice
|
September 2007 |
£145 |
8.75 % |
Breast Cancer
Therapeutic And Competitive Insights
|
February 2007 |
£1340 |
8.75 % |
Female Genital Prolapse and Urinary Incontinence
|
November 2007 |
£115 |
8.75 % |
Eu Paediatric Medicines Regulation
Boon or Burden?
|
January 2007 |
£1095 |
8.5 % |
Stakeholder Opinions: Fibromyalgia
Potentially lucrative market soon to become reality
|
May 2007 |
£2005 |
8.5 % |
How Drugs Are Developed
3rd Edition
|
January 2007 |
£1095 |
8.5 % |
How To Attract New Sports Nutrition Consumers
Using Mainstream Health Trends To Pitch Professional-Style Products
|
August 2006 |
£1475 |
8.4 % |
Bayer
Pipeline, Products ,Performance ,Potential
|
September 2008 |
£595 |
8.4 % |
Health and Wellness Healthcare Products in Spain
|
February 2007 |
£650 |
8.05 % |
Dietary supplements market in Poland 2009
Development forecasts 2009-2011
|
March 2009 |
£1285 |
8.05 % |
Nutraceuticals and Dietary Supplements Markets
|
September 2007 |
£2075 |
8.05 % |
GSK's Cervarix
A Future Blockbuster of 2007
|
March 2007 |
£1999 |
8.05 % |
Pipeline Insight: Breast Cancer
Recent approvals increase pressure on pipeline candidates
|
April 2008 |
£6000 |
8 % |
Stakeholder Opinions: Irritable Bowel Syndrome
Potentially profitable market is open for the taking
|
June 2007 |
£1900 |
8 % |
Urge Urinary Incontinence
Poor Differentiation Limiting New Product Uptake
|
April 2006 |
£8690 |
8 % |
Warner Chilcott Limited - SWOT Analysis
|
December 2008 |
£66 |
8 % |
Stakeholder Opinions: Irritable Bowel Syndrome
Potentially profitable market is open for the taking
|
June 2007 |
£1900 |
8 % |
CNS Drug Discoveries: Multiple Sclerosis
|
November 2006 |
£795 |
8 % |
Digestive Remedies in Chile
|
July 2008 |
£450 |
7.7 % |
Global Healthcare IT Investment Opportunities
Analysis and Forecasts to 2015
|
May 2009 |
£2440 |
7.7 % |
Eye Care in Switzerland
|
April 2009 |
£560 |
7.7 % |
Wound Treatments in Switzerland
|
April 2009 |
£560 |
7.7 % |
Hologic, Inc. Healthcare - Medical Equipment SWOT Report
|
August 2008 |
£76 |
7.7 % |
Diabetes Drug Discoveries 2009: what the future holds
|
February 2009 |
£795 |
7.7 % |
Qiagen N.V. Product Pipeline Analysis
|
August 2008 |
£460 |
7.7 % |
Digestive Remedies in Switzerland
|
April 2009 |
£560 |
7.7 % |
Wound Treatments in Chile
|
July 2008 |
£450 |
7.7 % |
Analgesics in Switzerland
|
April 2009 |
£560 |
7.7 % |
Eye Care in Chile
|
July 2008 |
£450 |
7.7 % |
Analgesics in Chile
|
July 2008 |
£450 |
7.7 % |
GE Healthcare Medical Device Company Intelligence Report
|
April 2009 |
£495 |
7.7 % |
Health and Wellness Healthcare Products in Norway
|
December 2006 |
£650 |
7.7 % |
GTx, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
7.5 % |
Warner Chilcott Limited - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
7.5 % |
Breast Cancer Drug Discoveries
What the future holds
|
December 2008 |
£795 |
7.5 % |
Medicated Skin Care in Switzerland
|
April 2009 |
£560 |
7.35 % |
Medicated Skin Care in Chile
|
July 2008 |
£450 |
7.35 % |
Vitamins And Dietary Supplements in Switzerland
|
April 2009 |
£560 |
7.35 % |
The Market for Minimally Invasive Medical Devices
|
March 2009 |
£2960 |
7.35 % |
NRT Smoking Cessation Aids in Switzerland
|
April 2009 |
£560 |
7.35 % |
Stakeholder Opinions: Hormonal Contraceptives
New directions in a competitive market
|
November 2006 |
£2005 |
7.35 % |
Disease Management and Drug Adherence
Strategies to support patients and enhance treatment persistence
|
July 2007 |
£3800 |
7 % |
China Pharmaceuticals and Healthcare Report Q4 2008
|
November 2008 |
£250 |
7 % |
Coloplast Medical Device Company Intelligence Report
|
February 2006 |
£395 |
7 % |
Cough, Cold And Allergy (Hay Fever) Remedies in Switzerland
|
April 2009 |
£560 |
7 % |
ScientiaVision Product Pinpoint: The New Vaccines
|
March 2009 |
£1825 |
6.65 % |
Multiplex Assays in Translational Medicine
Technologies, Applications, and Future Directions
|
February 2008 |
£685 |
6.65 % |
Chemotherapy Market Insights, 2006-2016
A Critical Analysis of Cancer Research, Treatments, Pipelines, and Commercial Opportunities
|
April 2006 |
£1900 |
6.65 % |
Hologic, Inc. Product Pipeline Analysis
|
August 2008 |
£460 |
6.65 % |
Pharmaceutical Wholesale and Distribution Industry Outlook & Analysis 2008, The
|
June 2008 |
£1499 |
6.65 % |
Future Product Opportunities in Cosmeceuticals
Innovation in food and drinks with beauty benefits
|
July 2007 |
£995 |
6.65 % |
Winning Pharmaceutical Brand Management
Maximizing brand value through best practice in brand development and product marketing
|
March 2006 |
£1495 |
6.65 % |
Endometriosis - Scientific Clarity Will Unlock Market Potential Stakeholder Opinions
|
December 2007 |
£2005 |
6.65 % |
The Cooper Companies, Inc.
Strategic Analysis Profile
|
February 2008 |
£480 |
6.65 % |
Medical Imaging Markets, Volume I
Radiography (X-Ray, Digital X-Ray, Fluoroscopy, Mammography, and Ct Markets)
|
February 2009 |
£2135 |
6.3 % |
Pipeline Insight Therapeutic Cancer Vaccines
A turbulent path from bench to bedside
|
October 2007 |
£3010 |
6.3 % |
Strategies and Solutions for Publication Planning and Execution Excellence
|
September 2007 |
£75 |
6.3 % |
Prostate and Breast Cancer
New Treatments & Developmental Progress
|
March 2007 |
£2025 |
6.3 % |
Stakeholder Opinion: Erectile Dysfunction
Identifying product differentiation and patient segmentation strategies
|
December 2006 |
£2005 |
6.3 % |
Sleep Disorders
Insomnia, Sleep Apnea, Restless Leg Syndrome, Bruxism, Narcolepsy and Sleepwalking
|
March 2009 |
£2075 |
5.95 % |
Biogen Idec: PharmaVitae Profile
PharmaVitae Profile
|
March 2007 |
£3010 |
5.95 % |
Transdermal Drug Delivery
Technologies, Markets and Companies
|
May 2009 |
£1525 |
5.95 % |
Commercial Insight: Osteoporosis
Risk management and reformulation offer best defense against generic onslaught
|
June 2007 |
£7600 |
5.95 % |
World market for cancer vaccines 2007-2012
|
January 2007 |
£1999 |
5.95 % |
Pipeline Insight: Anxiety Disorders
A decade of declining revenues
|
March 2006 |
£6495 |
5.95 % |
Wyeth Prospects to 2010
Performance, Products, Pipeline and Potential
|
July 2007 |
£595 |
5.95 % |
United States Healthcare IT Investment Opportunities
Analysis and Forecasts to 2015
|
March 2009 |
£1525 |
5.95 % |
Analysis of the Pharmaceutical Market to 2012 - Segmented by Drug Target Family
Sales & Marketing
|
October 2007 |
£3800 |
5.95 % |
Health and Wellness Healthcare Products in Belgium
|
November 2006 |
£650 |
5.6 % |
Merck & Co: PharmaVitae Profile
|
November 2006 |
£3000 |
5.6 % |
Obstetric Evidence-Based Guidelines
|
June 2007 |
£95 |
5.6 % |
The Cooper Companies, Inc. Healthcare - Medical Equipment SWOT Report
|
August 2008 |
£76 |
5.6 % |
GUIDED THERAPEUTICS, INC. Product Pipeline Analysis
|
August 2008 |
£460 |
5.6 % |
The Top 40 Manufacturers Of Orthopaedic Implants In Europe
|
May 2005 |
£240 |
5.5 % |
Partneringdesk deals and alliances in genitourinary and gynecological diseases
|
April 2006 |
£1250 |
5.5 % |
Stakeholder Opinions: Bladder Cancer
New drugs needed to challenge ineffective 20 year old drugs
|
November 2008 |
£2000 |
5.25 % |
Pfizer Prospects to 2010
Pipeline, Products,Performance,Potential
|
September 2007 |
£595 |
5.25 % |
Clinical Laboratory Services Market
(Growth Opportunities, Competitive Analysis and Competitor Profiles)
|
November 2008 |
£1525 |
5.25 % |
Hologic, Inc. Medical Equipment Company Share Analysis
|
September 2008 |
£610 |
5.25 % |
Physician Office Laboratory (POL) Testing Markets Worldwide
Status Quo and Future Trends
|
May 2007 |
£2135 |
5.25 % |
Pipeline Insight: Antiarrhythmics
RSD1235 in a class of its own
|
May 2006 |
£6495 |
4.9 % |
Pipeline Insight: Cancer Overview
Increasing Diversity Offers Both High Risk And Reward
|
September 2007 |
£7600 |
4.9 % |
Improve Market Research Impact
|
December 2008 |
£4695 |
4.9 % |
Disposable Medical Supplies Markets
|
April 2009 |
£2075 |
4.9 % |
Digene Corporation Product Pipeline Analysis
|
May 2008 |
£460 |
4.9 % |
Boston Scientific Corporation Product Pipeline Analysis
|
August 2008 |
£460 |
4.9 % |
HighGrowth Diagnostic Markets
|
November 2008 |
£2075 |
4.55 % |
Medical Imaging Markets
|
December 2008 |
£2075 |
4.55 % |
Digene Corporation Medical Equipment Company Share Analysis
|
July 2008 |
£610 |
4.55 % |
The Cardiovascular Disorders Market Outlook to 2012
|
February 2008 |
£1995 |
4.55 % |
Canadian Market for Gynecology & Urodynamics 2009
|
December 2008 |
£4575 |
4.55 % |
Stakeholder Opinions: Diabetic Renal Disease
|
November 2008 |
£2000 |
4.55 % |
Lateral Flow Technology and the Future of Point of Care Diagnostics
|
February 2007 |
£1825 |
4.55 % |
Pipeline Insight: Molecular Targeted Cancer Therapies Can anything else revolutionize the market?
- Cancer
|
October 2007 |
£7600 |
4.55 % |
Biotech in Autoimmune and Inflammatory Disease 2006
2nd Edition
|
May 2006 |
£1830 |
4.2 % |
U.S. Market for Over-the-Counter Pediatric Medication and Healthcare Products
|
March 2006 |
£1830 |
4.2 % |
Pediatric Health Care Products and Services
|
March 2009 |
£2960 |
4.2 % |
Patient Monitoring Markets
|
December 2008 |
£2075 |
4.2 % |
Merger and Acquisition Agreements in Pharma, Biotech and Diagnostics
|
February 2009 |
£1195 |
4.2 % |
Generic League
Market Analysis and Forecasts, 2007-2012, 2017 & 2022
|
February 2008 |
£1999 |
4.2 % |
Commercial Insight: Antidyslipidemics
Branded statins beware, generics are amongst you
|
July 2006 |
£8440 |
3.85 % |
Bladder Cancer Drug Pipeline Update 2009
|
January 2009 |
£855 |
3.5 % |
Indian Pharmaceutical Industry
|
July 2008 |
£2075 |
3.5 % |
Commercial Insight: Antihypertensives
New challenges for a maturing market
|
September 2006 |
£8000 |
3.5 % |
Monoclonal Antibodies Report Part I
|
June 2007 |
£3800 |
3.5 % |
Stryker Corporation Healthcare - Medical Equipment SWOT Report
|
August 2008 |
£76 |
3.5 % |
Neurodegenerative Disease Drug Market Analysis and Forecasts 2007
|
June 2007 |
£1999 |
3.5 % |
Bladder Cancer Drug Pipeline Update 2007
|
January 2009 |
£855 |
3.5 % |
What's Hot in Cancer Drug R&D?
|
July 2006 |
£295 |
3.5 % |
Personalized Medicine
Scientific & Commercial Aspects
|
May 2009 |
£2440 |
3.5 % |
Pipeline Insight: Non-Small Cell Lung Cancer
Pipeline set to offer only modest improvements
|
April 2008 |
£6000 |
3.15 % |
Stakeholder Opinions: Parkinson's Disease
Review of Key Commercial Opportunities in the Symptomatic Treatment Market
|
July 2006 |
£2230 |
3.15 % |
Pipeline Insight: HIV
Extending treatment options
|
September 2006 |
£6000 |
3.15 % |
Stryker Corporation Product Pipeline Analysis
|
August 2008 |
£460 |
3.15 % |
Pipeline and Commercial Insight: Anxiety Disorders Viable indication for antipsychotics companies
|
November 2008 |
£8000 |
3.15 % |
High-Growth Diagnostic Testing Markets
|
November 2008 |
£2075 |
3.15 % |
Breast Cancer Drug Pipeline Update 2006
|
January 2009 |
£1285 |
3 % |
Pain Therapeutics
Drugs, Markets and Companies
|
May 2009 |
£1830 |
2.8 % |
Global Market for Advanced Wound Care Products 2008, The
A complete review of this fast growing, highly innovative sector
|
April 2008 |
£695 |
2.8 % |
World Market for Prescription Cardiovascular Drugs
2nd Edition
|
November 2007 |
£2435 |
2.8 % |
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Breast- and Prostate Cancer
|
June 2007 |
£2365 |
2.8 % |
Terumo Medical Device Company Intelligence Report
|
February 2006 |
£295 |
2.8 % |
Stakeholder Opinions: Back Pain
Gain competitive edge by targeting subpopulations
|
March 2009 |
£2000 |
2.45 % |
Cytology and HPV Testing World Markets
|
July 2008 |
£2075 |
2.45 % |
Zimmer Holdings, Inc. Product Pipeline Analysis
|
August 2008 |
£460 |
2.45 % |
Zimmer Holdings, Inc. Healthcare - Medical Equipment SWOT Report
|
August 2008 |
£76 |
2.45 % |
China in Vitro Diagnostics Investment Opportunities
Analysis and Forecasts to 2015
|
April 2009 |
£1525 |
2.1 % |
Stryker Corporation Medical Equipment Company Share Analysis
|
September 2008 |
£610 |
2.1 % |
Parexel's Pharmaceutical R&D Statistical Sourcebook 2007/2008
|
May 2007 |
£260 |
2.1 % |
Stakeholder Opinions: Melanoma
Lucrative commercial opportunities persist
|
December 2006 |
£2005 |
2.1 % |
PAREXEL's Bio/Pharma R&D Statistical Sourcebook 2008/2009
|
June 2008 |
£260 |
2.1 % |
Commercial and Pipeline Insight: Hepatitis B
|
October 2007 |
£7600 |
1.75 % |
Canadian Market for Endoscopic Devices 2009 (8 Reports in 1)
|
December 2008 |
£10675 |
1.75 % |
Pipeline And Commercial Insight
Pediatric And Adolescent Vaccines
|
July 2007 |
£8000 |
1.75 % |
Stakeholder Insight: Psoriasis
Biologics are yet to make topical treatments obsolete
|
March 2009 |
£8000 |
1.75 % |
United States Nephrology and Urology Devices Investment Opportunities
Analysis and Forecasts to 2015
|
April 2009 |
£1525 |
1.75 % |
Global Protein Therapeutics Market, The
Market Dynamics and Pipeline Analysis
|
December 2006 |
£1830 |
1.4 % |
The Global Pain Therapeutics Market
Market Analysis, R&D Pipelines and Competitive Landscape
|
October 2007 |
£1830 |
1.4 % |
Cardiovascular Catherers and Systems
|
January 2007 |
£2350 |
1.4 % |
Cell Therapy
Technologies, Markets and Companies
|
May 2009 |
£2745 |
1.05 % |
